William Blair Keeps a Buy Rating on Aptinyx (APTX)


William Blair analyst Myles Minter reiterated a Buy rating on Aptinyx (APTX) on October 20. The company’s shares closed last Friday at $3.13.

According to TipRanks.com, Minter is a 4-star analyst with an average return of 14.5% and a 28.1% success rate. Minter covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Minerva Neurosciences, and Prevail Therapeutics.

Currently, the analyst consensus on Aptinyx is a Strong Buy with an average price target of $10.00, a 219.5% upside from current levels. In a report issued on October 20, Cowen & Co. also maintained a Buy rating on the stock.

See today’s analyst top recommended stocks >>

Based on Aptinyx’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $490K and GAAP net loss of $12.52 million. In comparison, last year the company earned revenue of $925K and had a GAAP net loss of $12.13 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts